EMPA-REG Trial: Implications for Type 2 Diabetes Treatment, CV Risk Reduction
November 14th 2017In this clip, Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center, discusses how the EMPA-REG trial is a huge step forward for health care providers being able to treat patients with type 2 diabetes with medications that also reduce cardiovascular risk.
Read More